Observational studyThe Journal of international medical research2026
Retrospective observational assessment of the safety, performance, and utility of an antimicrobial/antithrombogenic peripherally inserted central catheter in pediatric patients.
Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundTo determine the safety and performance of an antimicrobial/antithrombogenic peripherally inserted central catheter, a retrospective cohort study was conducted.MethodsData were collected using chart audits by clinicians in the US, UK, and EU in 2021 and 2022 for patients requiring an antimicrobial/antithrombogenic peripherally inserted central catheter. The primary outcome endpoint was successful completion of treatment without elective device removal due to adverse events. The secondary outcome endpoint was the incidence of device-related adverse events. Following the initial analysis of the index study, which included adult and pediatric patients, data from additional pediatric cases were collected. Charts lacking primary endpoint data were excluded. Standard descriptive statistics and analyses of categorical variables were performed without adjustment and with minimal stratification.ResultsA total of 38 healthcare providers collected data for 175 evaluable cases, of which 54.3% were male. The duration of use ranged from less than 1 day to 253 days. Treatment was successfully completed without elective device removal due to adverse events in 90.3% of cases. In 18 cases (10.3%), the patients experienced adverse events, with a total of 21 device-related adverse events reported, corresponding to 5 events per 1000 catheter days. None of the reported events were deemed serious or unexpected.ConclusionsThese findings suggest the potential for safe use of the antimicrobial/antithrombogenic peripherally inserted central catheter in the pediatric patient population, with no elective device removal due to adverse events in 90% of cases. No cases of central line-associated bloodstream infection, thrombosis, or anaphylaxis were reported; however, these findings should be interpreted with caution given the moderate sample size and the rarity of such events in general practice. Owing to the limitations of this study, including the risk of bias inherent to retrospective studies, prospective controlled trials with rigorous outcome assessments are needed to confirm these observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.